Catalyst Pharmaceuticals, Inc.
CPRX
$24.40
$0.160.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.61% | 15.31% | 19.44% | 43.56% | 28.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.61% | 15.31% | 19.44% | 43.56% | 28.26% |
| Cost of Revenue | 9.59% | 12.19% | 35.79% | 44.35% | 43.08% |
| Gross Profit | 7.18% | 15.97% | 16.56% | 43.42% | 25.43% |
| SG&A Expenses | 20.88% | 3.47% | 12.81% | -0.06% | 5.13% |
| Depreciation & Amortization | 1.29% | -0.01% | 0.00% | 0.01% | 3.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.93% | 5.58% | 17.24% | 9.35% | 14.67% |
| Operating Income | -1.59% | 30.17% | 22.22% | 133.60% | 50.73% |
| Income Before Tax | -3.07% | 24.18% | 24.21% | 145.06% | 58.82% |
| Income Tax Expenses | 5.25% | 37.02% | 14.61% | 150.24% | 53.80% |
| Earnings from Continuing Operations | -5.79% | 20.28% | 27.73% | 143.77% | 60.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.79% | 20.28% | 27.73% | 143.77% | 60.53% |
| EBIT | -1.59% | 30.17% | 22.22% | 133.60% | 50.73% |
| EBITDA | -1.27% | 25.39% | 18.96% | 99.22% | 42.23% |
| EPS Basic | -8.10% | 16.67% | 23.55% | 134.37% | 42.91% |
| Normalized Basic EPS | -0.91% | 27.93% | 20.39% | 118.29% | 39.29% |
| EPS Diluted | -6.46% | 20.00% | 24.24% | 136.84% | 41.39% |
| Normalized Diluted EPS | 0.66% | 30.15% | 21.61% | 120.71% | 40.95% |
| Average Basic Shares Outstanding | 2.52% | 3.09% | 3.37% | 3.99% | 12.35% |
| Average Diluted Shares Outstanding | 0.91% | 1.34% | 2.32% | 2.88% | 11.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |